Skip to main content
Signal8
Launch Terminal

Annexon, Inc. (ANNX)

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Annexon, Inc. logo

Annexon, Inc.

NASDAQ:ANNXHealthcare
+1.00%$4.05
AH$4.08+0.74%vs close
Mkt Cap$767.8M
Float153.79M
O/S189.58M
Vol
$ Vol
RVOL
Inst Own94.5%
SI20.6%
Earnings
Dilution
Annexon, Inc. logoNASDAQ:ANNX$4.05+1.00%
Phase Distribution
16 lead-sponsored trials·2 active·12 completed
Phase 18
Phase 24
Phase 34
Status Overview
Not yet recruiting1
Recruiting1
Active, not recruiting1
Completed12
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

    ANX005, Placebo

    Guillain-Barre Syndrome

    Enrollment
    242
    Start
    Dec 2020
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT04701164
  • Phase 3
    Active, not recruiting

    A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

    Vonaprument

    Geographic Atrophy

    Enrollment
    659
    Start
    Jul 2024
    Primary Completion
    Jul 2027est.
    Completion
    Jul 2027est.
    NCT06510816
  • Phase 3
    Recruiting

    An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

    Tanruprubart

    Guillain-Barre Syndrome

    Enrollment
    30
    Start
    Sep 2025
    Primary Completion
    May 2027est.
    Completion
    Jun 2028est.
    NCT07020819
  • Phase 3
    Not yet recruiting

    An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

    Vonaprument

    Geographic Atrophy

    Enrollment
    605
    Start
    Sep 2026est.
    Primary Completion
    Jul 2029est.
    Completion
    Jul 2029est.
    NCT07807969
  • Phase 2
    Completed

    An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease

    ANX005

    Huntington Disease

    Enrollment
    28
    Start
    Sep 2020
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT04514367
  • Phase 2
    Completed

    Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

    ANX005

    Amyotrophic Lateral Sclerosis

    Enrollment
    17
    Start
    Jan 2021
    Primary Completion
    Jan 2024
    Completion
    Apr 2024
    NCT04569435
  • Phase 2
    Completed

    A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

    ANX007

    Geographic Atrophy

    Enrollment
    270
    Start
    Feb 2021
    Primary Completion
    Mar 2023
    Completion
    Sep 2023
    NCT04656561
  • Phase 2
    Completed

    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

    ANX005

    Warm Autoimmune Hemolytic Anemia (wAIHA)

    Enrollment
    7
    Start
    Nov 2021
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT04691570
  • Phase 1
    Terminated

    Single Dose Study of ANX005 in Healthy Volunteers

    ANX005, IVIg

    Safety and Tolerability in Healthy Volunteers

    Enrollment
    27
    Start
    Dec 2016
    Primary Completion
    Jun 2018
    Completion
    Jun 2018
    NCT03010046
  • Phase 1
    Completed

    Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

    ANX007

    Open-angle Glaucoma

    Enrollment
    9
    Start
    Mar 2018
    Primary Completion
    Aug 2018
    Completion
    Aug 2018
    NCT03488550
  • Phase 1
    Completed

    A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

    ANX005, Intravenous immunoglobulin

    Guillain-Barré Syndrome

    Enrollment
    14
    Start
    Jan 2020
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04035135
  • Phase 1
    Completed

    Study of ANX007 in Participants With Primary Open-angle Glaucoma

    2.5mg ANX007, 5.0mg ANX007

    Open Angle Glaucoma

    Enrollment
    17
    Start
    Jul 2018
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT04188015
  • Phase 1
    Completed

    A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

    ANX009, Placebo

    Safety and Tolerability in Healthy Volunteers

    Enrollment
    48
    Start
    Oct 2020
    Primary Completion
    Jun 2021
    Completion
    Jun 2021
    NCT04535752
  • Phase 1
    Completed

    Single Ascending Dose Study of ANX105

    ANX105, Placebo

    Healthy

    Enrollment
    23
    Start
    Feb 2022
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT05288881
  • Phase 1
    Completed

    Dose Study of ANX1502 in Healthy Volunteers

    ANX1502, Placebo

    Healthy

    Enrollment
    135
    Start
    Jun 2022
    Primary Completion
    Nov 2024
    Completion
    Nov 2024
    NCT05521269
  • Phase 1
    Completed

    A Study of ANX009 in Adult Participants With Lupus Nephritis

    ANX009

    Lupus Nephritis

    Enrollment
    7
    Start
    Aug 2022
    Primary Completion
    Aug 2023
    Completion
    Oct 2023
    NCT05780515
Search ClinicalTrials.gov for “Annexon”